PCE

Podcast 2: What’s New in Disease-Modifying Therapy

Episode Summary

In this podcast, multiple sclerosis (MS) experts Stephen Krieger, MD and Allison Boyd, MPAS, PA-C, MSCS discuss current data supporting the use of the many available disease-modifying therapies for MS and the importance of shared decision-making in providing optimal care for patients.

Episode Notes

In this episode, Stephen Krieger, MD, and Allison Boyd, MPAS, PA-C, MSCSdiscuss the expanding treatment armamentarium for MS, the complexities involved in making treatment selection, patient factors to consider when individualizing treatment, and how best to talk with patients about their options within the context of shared decision-making.

Stephen Krieger, MD: consultant/advisor/speaker: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics; researcher: Biogen, Bristol-Myers Squibb, Novartis, Sanofi.

Allison L. Boyd, MPAS, PA-C, MSCS: consultant/advisor/speaker: EMD Serono.